Metastatic Colorectal Cancers Recruiting Phase 3 Trials for Cetuximab (DB00002)

Also known as: Colorectal Cancer Metastatic / Metastatic Colorectal Cancer / Metastatic Colorectal Cancer (MCRC) / Cancer - Metastatic Colorectal / Colorectal Cancer, Metastatic

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04008030A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Treatment
NCT03803553Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerTreatment
NCT03391934A Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer PatientsTreatment
NCT03206151CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal CancerTreatment
NCT02934529Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus CetuximabTreatment
NCT01910610Multi-Line Therapy Trial in Unresectable Metastatic Colorectal CancerTreatment